SCHEMBL3488972

SCHEMBL3488972

Cc1ccc(S(=O)(=O)NC(=N)NCCCCCCO)cc1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.53
LMNA P02545 2/20 0.53
ALB P02768 1/20 0.53
CYP2C9 P11712 1/20 0.53
TSHR P16473 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
FBP1 P09467 5/20 0.45
HTT P42858 1/20 0.44
NPSR1 Q6W5P4 2/20 0.44
CA2 P00918 2/20 0.43
CA12 O43570 1/20 0.43
CA9 Q16790 1/20 0.43
ALOX15 P16050 1/20 0.43
CA1 P00915 1/20 0.42
MMP1 P03956 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP8 P22894 1/20 0.42
MMP13 P45452 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3489662 0.88 ALDH1A1 (0.51) ALDH1A1LMNAALBCYP2C9TSHR
SCHEMBL11058142 0.84 ALDH1A1 (0.55) ALDH1A1LMNAALBCYP2C9TSHR
SCHEMBL27538377 0.84 ALDH1A1 (0.54) ALDH1A1LMNAALBCYP2C9TSHR
SCHEMBL30490037 0.79 CA12 (0.67) ALDH1A1LMNAHTTNPSR1CA2
SCHEMBL3490607 0.79 RAB9A (0.46) ALDH1A1LMNAALBCYP2C9TSHR
SCHEMBL9316028 0.78 MMP2 (0.61) ALDH1A1LMNACYP2C9TDP1NPSR1
SCHEMBL4095386 0.78 ALDH1A1 (0.48) ALDH1A1LMNAALBCYP2C9TSHR
SCHEMBL4433373 0.77 ALDH1A1 (0.50) ALDH1A1LMNAALBCYP2C9TSHR
SCHEMBL29438757 0.77 ALDH1A1 (0.50) ALDH1A1LMNAALBCYP2C9TSHR
SCHEMBL27513081 0.77 ALDH1A1 (0.50) ALDH1A1LMNAALBCYP2C9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150359899-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS BOTTI PAOLO (CH) 2015-12-17 US disclosed
US-9211340-B2 Means and methods of enhancing delivery to biological systems CAPSUGEL BELGIUM (BE) 2015-12-15 US disclosed
EP-2561891-A2 Means and methods of enhancing delivery to biological systems Botti, Paolo (CH) 2013-02-27 EP disclosed
US-20100062050-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS CAPSUGEL BELGIUM (BE) 2010-03-11 US disclosed
CN-101557829-A Apparatus and method for enhancing delivery to biological systems PAOLO BOTTI (CH) 2009-10-14 CN disclosed
EP-2068936-A2 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS Botti, Paolo (CH) 2009-06-17 EP disclosed
WO-2008037463-A2 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS BOTTI PAOLO (CH) 2008-04-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100062050-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS SGTA, GHRHR, IL36G ALDH1A1 1259/4885LMNA 3031/4885ALB 113/4885
US-20150359899-A1 MEANS AND METHODS OF ENHANCING DELIVERY TO BIOLOGICAL SYSTEMS PTMS, HGFAC, SLC43A1 ALDH1A1 1096/4885LMNA 1616/4885ALB 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.